Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Immunitybio Inc

IBRX
Current price
3.43 USD +0.04 USD (+1.18%)
Last closed 3.72 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 523 924 992 USD
Yield for 12 month -44.23 %
Week
Month
Year
IBRX
21.11.2021 - 28.11.2021

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California. Address: 3530 John Hopkins Court, San Diego, CA, United States, 92121

Analytics

WallStreet Target Price

4.5 USD

P/E ratio

Dividend Yield

Current Year

+240 000 USD

Last Year

+934 000 USD

Current Quarter

+82 000 USD

Last Quarter

+41 000 USD

Current Year

+240 000 USD

Last Year

+934 000 USD

Current Quarter

+82 000 USD

Last Quarter

+41 000 USD

Key Figures IBRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -341 956 992 USD
Operating Margin TTM -97726.83 %
PE Ratio
Return On Assets TTM -57.48 %
PEG Ratio
Return On Equity TTM
Wall Street Target Price 4.5 USD
Revenue TTM 556 000 USD
Book Value -0.62 USD
Revenue Per Share TTM 0.001 USD
Dividend Share
Quarterly Revenue Growth YOY -30.5 %
Dividend Yield
Gross Profit TTM 240 000 USD
Earnings Share -1.04 USD
Diluted Eps TTM -1.04 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics IBRX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History IBRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation IBRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 5500.1319
Price Sales TTM 4539.4336
Enterprise Value EBITDA -9.7415
Price Book MRQ

Financials IBRX

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators IBRX

For 52 weeks

1.21 USD 7.1 USD
50 Day MA 2.57 USD
Shares Short Prior Month 41 921 543
200 Day MA 2.41 USD
Short Ratio 3.74
Shares Short 35 658 525
Short Percent 27.17 %